Clinical trial NCT02440802 - References

Prostate Cancer — Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer

Citation(s)

•   Alevizaki M, Cimponeriu AT, Garofallaki M, Sarika HL, Alevizaki CC, Papamichael C, Philippou G, Anastasiou EA, Lekakis JP, Mavrikakis M
  The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol (Oxf). 2003 Dec;59(6):749-55.
•   Allain TJ
  Prostate cancer, osteoporosis and fracture risk. Gerontology. 2006;52(2):107-10. Review.
•   Benton MJ, White A
  Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs. 2006 Winter;23(4):201-11. Review.
•   Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S
  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979-83.
•   Crandall CJ, Crawford SL, Gold EB
  Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med. 2006 Sep;119(9 Suppl 1):S52-60.
•   D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH
  Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007 May 15;109(10):2004-10.
•   D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW
  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10;25(17):2420-5.
•   D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH
  Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006 Sep 1;24(25):4190-5.
•   Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR
  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004 Mar 1;100(5):892-9. Review.
•   Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR
  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.
•   Elfassihi L, Giroux S, Bureau A, Laflamme N, Cole DE, Rousseau F
  Association with replication between estrogen-related receptor gamma (ESRRgamma) polymorphisms and bone phenotypes in women of European ancestry. J Bone Miner Res. 2010 Apr;25(4):901-11. doi: 10.1359/jbmr.091014.
•   Fox CS, Yang Q, Cupples LA, Guo CY, Atwood LD, Murabito JM, Levy D, Mendelsohn ME, Housman DE, Shearman AM
  Sex-specific association between estrogen receptor-alpha gene variation and measures of adiposity: the Framingham Heart Study. J Clin Endocrinol Metab. 2005 Nov;90(11):6257-62. Epub 2005 Sep 6.
•   Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R
  Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.
•   Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU
  Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12(2):198-203. doi: 10.1038/pcan.2008.51. Epub 2008 Oct 14.
•   Jim HS, Park JY, Permuth-Wey J, Rincon MA, Phillips KM, Small BJ, Jacobsen PB
  Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun. 2012 Oct;26(7):1030-6. doi: 10.1016/j.bbi.2012.03.001. Epub 2012 Mar 28.
•   McGrath SA, Diamond T
  Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol. 1995 Aug;154(2 Pt 1):535-6.
•   Mohile SG, Mustian K, Bylow K, Hall W, Dale W
  Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009 Jun;70(3):235-55. doi: 10.1016/j.critrevonc.2008.09.004. Epub 2008 Oct 25. Review.
•   Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A
  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.
•   Moyad MA
  Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005 Jan-Feb;23(1):56-64. Review.
•   Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M
  Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001 Nov;166(5):1724-8.
•   Rodríguez-González G, Ramírez-Moreno R, Pérez P, Bilbao C, López-Ríos L, Díaz-Chico JC, Lara PC, Serra-Majem L, Chirino R, Díaz-Chico BN
  The GGN and CAG repeat polymorphisms in the exon-1 of the androgen receptor gene are, respectively, associated with insulin resistance in men and with dyslipidemia in women. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):202-8. doi: 10.1016/j.jsbmb.2008.12.009. Epub 2008 Dec 30.
•   Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M
  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20;26(6):842-7. doi: 10.1200/JCO.2007.13.6804.
•   Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D
  Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA. 2003 Nov 5;290(17):2263-70. Erratum in: JAMA. 2004 Jan 14;291(2):186.
•   Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS
  Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.
•   Smith MR, O'Malley AJ, Keating NL
  Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008 Jun;101(11):1335-6. doi: 10.1111/j.1464-410X.2008.07707.x.

Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer

Details for clinical trial NCT02440802